For decades, doctors treating moderate to severe pain faced an impossible bargain: prescribe opioids that work, but risk addiction, or offer weaker alternatives that leave patients suffering. Now, a quietly revolutionary drug is changing the equation.
Suzetrigine, sold under the brand name Journavx and made by Vertex Pharmaceuticals, was approved by the US Food and Drug Administration in January 2025 as the first in an entirely new class of non-opioid painkillers — the first major innovation in pain management in more than 20 years. Experts say it could mark a turning point in the fight against the opioid crisis.
How it works
Unlike opioids, which act on the brain's central nervous system and can trigger the euphoric highs that lead to addiction, suzetrigine takes a fundamentally different approach. It selectively blocks a sodium channel called NaV1.8, found exclusively in peripheral pain-sensing neurons — the nerves that detect injury and send pain signals to the brain.
By intercepting those signals before they reach the brain, suzetrigine delivers pain relief without the sedation, respiratory depression, or abuse potential that make opioids so dangerous. According to research published by the CAS Science Team, the drug achieves over 31,000-fold selectivity for pain pathways while sparing other tissues, including the heart and brain.
"For pain physicians, the holy grail of medication management is something that can block pain with no side effects," Dr Robert Chow, a Yale Medicine anaesthesiologist and pain management specialist, told Yale Medicine. "The ideal scenario is one that works as well as opioids, but without the untoward side effects."
What the trials showed
The FDA's approval was based on two large clinical trials involving more than 2,000 patients experiencing moderate to severe pain after surgery. Participants who received suzetrigine reported pain relief comparable to hydrocodone/acetaminophen (commonly known as Vicodin), and both medications significantly outperformed a placebo.
A further open-label study of 256 patients found that 83% rated suzetrigine as providing "good" to "excellent" pain relief, with no serious drug-related adverse events such as respiratory depression or sedation. The most common side effects were mild: itching, muscle spasms, and rash.
The FDA granted suzetrigine Breakthrough Therapy, Fast Track, and Priority Review designations — a clear signal of how urgently regulators viewed the need for opioid alternatives.
Why it matters now
The scale of the opioid crisis lends this breakthrough genuine urgency. Between 1999 and 2022, nearly 727,000 people in the United States died from opioid overdoses, according to the Centers for Disease Control and Prevention. Though opioid-related deaths have finally begun to decline, more than 50,000 Americans still die from overdoses each year.
Suzetrigine is currently approved only for acute (short-term) pain, and at $15.50 per pill — compared with roughly $1–2 for generic Vicodin — cost and insurance coverage remain open questions. Trials exploring its effectiveness for chronic conditions such as diabetic neuropathy are ongoing, though results for sciatica have so far been less promising.
A first step, not the last
Dr Stephen Waxman, the Yale neuroscientist whose research over 25 years ago identified NaV1.8's role in pain signalling, described suzetrigine as a milestone — not because it is perfect, but because it proves the concept works.
"This is a first step," Dr Waxman said. "We have more work to do, but I expect that next-generation drugs will be even better."
Several major pharmaceutical companies, including Pfizer and GSK, are now developing their own NaV1.8 inhibitors, suggesting suzetrigine may be the first of many. For the millions of people living with pain — and the families devastated by opioid addiction — that is genuinely hopeful news.
